BioPharma Resources

Drug Trial Radar · NCT06499285

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

225

Planned (sponsor's estimate)

Start

May 6, 2025

Primary completion

Sep 15, 2028

Study completion Mar 5, 2032

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jul 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.

Conditions

  • Myelodysplastic Syndromes

Interventions

  • ElriterceptDrug

    Elritercept (TAK-226, KER-050) administered subcutaneously every 4 weeks.

  • PlaceboDrug

    Elritercept (TAK-226, KER-050) matching-placebo administered subcutaneously every 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Transfusion Independence (TI) for ≥8 WeeksTime frame: Baseline through Week 24

Locations

182 sites in 26 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • Los Angeles Cancer Network

    Glendale, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • Smilow Cancer Hospital at Yale-New Haven

    New Haven, Connecticut · Recruiting

  • University of Miami Hospital and Clinics

    Miami, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • ILCC. Illinois Cancer Centers

    Peoria, Illinois · Recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • Ghattas Oncology

    Monroe, Louisiana · Recruiting

  • Maryland Oncology Hematolofy

    Columbia, Maryland · Recruiting

  • MidAmerica Cancer Care

    Kansas City, Missouri · Recruiting

  • Comprehensive Cancer Centers of Nevada

    Henderson, Nevada · Recruiting

  • Clinical Research Alliance NY

    Westbury, New York · Recruiting

  • Novant Health-Cancer Institute

    Winston-Salem, North Carolina · Recruiting

  • Gabrail Cancer Center Research

    Canton, Ohio · Recruiting

  • Cleveland Clinic - Cleveland

    Cleveland, Ohio · Recruiting

  • Tennessee Cancer Specialists

    Knoxville, Tennessee · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Texas Oncology Northeast Texas

    Denison, Texas · Recruiting

  • U.T. MD Anderson Cancer Center, Division of Cancer Medicine

    Houston, Texas · Recruiting

  • LUMI Research

    Houston, Texas · Recruiting

  • Epic Medical Research

    Red Oak, Texas · Recruiting

  • Texas Oncology Gulf Coast

    The Woodlands, Texas · Recruiting

  • Tranquil Research

    Webster, Texas · Recruiting

  • Epic Care Emeryville

    Issaquah, Washington · Not yet recruiting

  • The Canberra Hospital

    Garran, Australian Capital Territory, Australia · Not yet recruiting

  • Westmead Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Townsville University Hospital

    Douglas, Queensland, Australia · Recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Recruiting

  • Flinders Medical Centre

    Adelaide, South Australia, Australia · Recruiting

  • Box Hill Hospital

    Box Hill, Victoria, Australia · Recruiting

  • St Vincent's Hospital (Melbourne) Ltd

    Fitzroy, Victoria, Australia · Recruiting

  • Alfred Health

    Melbourne, Victoria, Australia · Not yet recruiting

  • Peter MacCallum Cancer Center

    Parkville, Victoria, Australia · Recruiting

  • Americas Institute

    Rio de Janeiro, Brazil · Recruiting

  • Portuguese Charity of Sao Paulo, Clinical Hematology / Oncology Center

    São Paulo, Brazil · Recruiting

  • Hospital A.C.Camargo ("Antonio Prudente" Foundation)

    São Paulo, Brazil · Recruiting

  • Santa Casa of Mercy of Santos

    São Paulo, Brazil · Recruiting

  • Hosptial Erasto Gaertner

    Curitiba, Paraná, Brazil · Recruiting

  • Porto Alegre Clinical Hospital (HCPA)

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

Showing 40 of 182 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.